Q-omics provides the consensus-scored NRG3 profile across patient tissues and cancer cell-line models. NRG3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NRG3 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, NRG3 RNA expression shows 16,505 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where NRG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRG3 survival associations across molecular data types. NRG3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRG3 RNA expression–survival associations across cancer types. High NRG3 expression shows unfavorable associations in BLCA, STAD and UCEC, but favorable associations in HNSC, LGG and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NRG3 RNA expression.
This table summarizes NRG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NRG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRG3 shows lower tumor expression in COAD, LUAD, LUSC and THCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher NRG3 RNA expression in tumor versus normal tissue (log2 FC = +1.416, t-test p < 0.001).
This table shows molecular features associated with NRG3 in patient tissues and cancer cell lines. In patient samples, NRG3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NRG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
